Patent · US Active

2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors

US10179123B2 · kind B2 · utility

4Cited by

2References

15Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Olaf Panknin · Berlin, DE
Katja Zimmermann · Mülheim an der Ruhr, DE
Roland Neuhaus · Berlin, DE

Key dates

Filing date	Jul 4, 2016
Grant date	Jan 15, 2019
Priority date	—
Expiry date	Jul 4, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to 2-Aryl- and 2-Arylalkyl-benzimidazoles of general formula (I): in which A, R1, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.